Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease

TUCSON, AZ / ACCESSWIRE / September 21, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory and anti-fibrosis therapeutic platform for serious unchecked inflammatory and fibrotic disorders, has been awarded two 3-year NIH FAST-TRACK AWARDS [R42DK135208; R42HL160422) to support development of ALT-100, a humanized monoclonal antibody (mAb) therapy for the chronic indications of Pulmonary Arterial Hypertension (PAH) and Inflammatory Bowel Disease (IBD). The ALT-100 mAb targets the inflammation-inducing damage-associated molecular pattern protein eNAMPT, and is currently in Phase 1A human safety trials.

Continue reading

Arizona Alzheimer’s Disease Research Center (ADRC) Development Grant: Request for Proposals

APPLICATION RECEIPT DATE:
Optional Pre-proposal Deadline: September 30, 2022 Full Application Deadline: October 28, 2022 Anticipated Start Date: July 1, 2023

PURPOSE: The Arizona Alzheimer’s Disease Research Center (ADRC) invites applications for development grant proposal studies to support basic or clinical biomedical, translational, epidemiological, caregiving, educational, or behavioral studies in AD, ADRD or brain aging research. Developmental projects are intended to help establish the basis for applying for further research funding and further development of the applicant’s career in these areas of research.

Continue reading

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

 

 

 

 

 

 

TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.Continue reading

Decreased PEMT Gene Expression In The Liver Is Linked To Severity In Nonalcoholic Fatty Liver Disease

PHOENIX, Ariz. — August 22, 2022 — Nonalcoholic fatty liver disease (NAFLD) is both increasingly common and potentially deadly; yet its causes remain poorly understood. Now, a collaborative team of researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, and Temple University has uncovered a link between decreases in an enzyme that makes choline in the liver —an essential nutrient for humans— and severity of NAFLD.

Continue reading